<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660890</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN2050-HV-107</org_study_id>
    <nct_id>NCT04660890</nct_id>
  </id_info>
  <brief_title>A Study of the Cardiac Effects of ALXN2050 in Healthy Adults</brief_title>
  <official_title>A Multiple-Ascending-Dose, Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled Study to Evaluate the Effect of ALXN2050 on the QT Interval in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel&#xD;
      study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants randomized to the treatment arm will receive ALXN2050 in a multiple-ascending&#xD;
      doses fashion over 3 periods (treatment sequence ABC). Participants randomized to the control&#xD;
      arms will be further randomized to 1 of 2 treatment sequences (treatment sequence DEF or GHI)&#xD;
      to receive placebo or active control over 3 periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected Change From Baseline QTc Intervals (ddQTc) For ALXN2050</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
    <description>Twelve-lead electrocardiograms (ECGs) will be extracted from continuous (Holter) recordings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline PR Interval (dPR) For ALXN2050</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
    <description>Twelve-lead ECGs will be extracted from continuous (Holter) recordings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ddQTc For Moxifloxacin</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
    <description>Twelve-lead ECGs will be extracted from continuous (Holter) recordings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration-time Curve During A Dosing Interval (tau) At Steady-state (AUCtau) For ALXN2050</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration Following Multiple Dosing (Cmax,ss) For ALXN2050</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Maximum Observed Plasma Concentration Following Multiple Dosing (Tmax,ss) For ALXN2050</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (postdose) through follow-up (7 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Arm (ABC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Sequence ABC - Participants will receive all 3 doses of ALXN2050 in a multiple-ascending fashion over 3 periods:&#xD;
Treatment A (Period 1): ALXN2050 Dose 120 milligrams (mg) and moxifloxacin-matching placebo.&#xD;
Treatment B (Period 2): ALXN2050 Dose 240 mg and moxifloxacin-matching placebo.&#xD;
Treatment C (Period 3): ALXN2050 Dose 360 mg and moxifloxacin-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm (DEF)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment Sequence DEF - Participants will receive ALXN2050-matching placebo over 3 periods:&#xD;
Treatment D (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.&#xD;
Treatment E (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin.&#xD;
Treatment F (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm (GHI)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment Sequence GHI - Participants will receive ALXN2050-matching placebo over 3 periods:&#xD;
Treatment G (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin.&#xD;
Treatment H (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.&#xD;
Treatment I (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN2050</intervention_name>
    <description>ALXN2050 will be administered orally twice daily as powder-in-capsule.</description>
    <arm_group_label>Treatment Arm (ABC)</arm_group_label>
    <other_name>ACH-0145228 (formerly)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN2050-matching Placebo</intervention_name>
    <description>ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.</description>
    <arm_group_label>Control Arm (DEF)</arm_group_label>
    <arm_group_label>Control Arm (GHI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin will be administered as a single oral dose.</description>
    <arm_group_label>Control Arm (DEF)</arm_group_label>
    <arm_group_label>Control Arm (GHI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin-matching Placebo</intervention_name>
    <description>Moxifloxacin-matching placebo will be administered as a single oral dose.</description>
    <arm_group_label>Control Arm (DEF)</arm_group_label>
    <arm_group_label>Control Arm (GHI)</arm_group_label>
    <arm_group_label>Treatment Arm (ABC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50.0 kg at screening.&#xD;
&#xD;
          2. No clinically significant history or presence of ECG abnormalities at screening.&#xD;
&#xD;
          3. Female participants must be of non-childbearing potential and need not employ a method&#xD;
             of contraception.&#xD;
&#xD;
          4. Non-sterile male participants must agree to abstinence or use a highly effective&#xD;
             method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant laboratory abnormalities.&#xD;
&#xD;
          2. History of any medical or psychiatric condition or disease that might limit the&#xD;
             participant's ability to complete or participate in this clinical study, confound the&#xD;
             results of the study, or pose an additional risk to the participant by their&#xD;
             participation in the study.&#xD;
&#xD;
          3. History or presence of drug or alcohol abuse within previous 2 years, current tobacco&#xD;
             and/or nicotine user, or positive alcohol and/or drug screen at screening or Day -1 of&#xD;
             Period 1.&#xD;
&#xD;
          4. History or presence of clinically significant seizures, head injury, or head trauma.&#xD;
&#xD;
          5. History of procedures that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          6. History of meningococcal infection, or a first-degree relative with a history of&#xD;
             meningococcal infection.&#xD;
&#xD;
          7. History of significant multiple and/or severe allergies or has had an anaphylactic&#xD;
             reaction or significant intolerability to prescription or non-prescription drugs.&#xD;
&#xD;
          8. Body temperature ≥ 38.0°Celsius at screening or prior to first dosing in Period 1 or&#xD;
             history of febrile illness, or other evidence of infection, within 14 days prior to&#xD;
             (first) dosing.&#xD;
&#xD;
          9. Donation of whole blood from 3 months prior to first dosing, or of plasma from 30 days&#xD;
             before first dosing, or receipt of blood products within 6 months prior to first&#xD;
             dosing.&#xD;
&#xD;
         10. Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives (if known) or 30 days before&#xD;
             first dosing, whichever is longer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALXN2050</keyword>
  <keyword>Electrocardiogram</keyword>
  <keyword>QT Interval</keyword>
  <keyword>Concentration-QT</keyword>
  <keyword>Factor D Inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

